1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Spectrum Sinks After Poziotinib Fail In NSCLC

Shares Slide 60%

 
• By Kevin Grogan

The US firm has two assets but the future looks less than rosy for one of them, the lung cancer therapy poziotinib, after the drug failed a Phase II study.

SC1805_Falling OffHorse_585258497_1200.jpg
Spectrum takes a tumble after trial disappointment • Source: Shutterstock

Shares in Spectrum Pharmaceuticals Inc. have taken a battering on the news that the US firm's investigational lung cancer drug poziotinib failed to meet its main goal in a mid-stage clinical trial.

The Nevada-headquartered group reported that the primary endpoint in its Phase II trial called Zenith20 evaluating poziotinib in previously treated non-small cell lung cancer patients with epidermal growth factor receptor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

More from R&D

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.